Literature DB >> 20156068

Diagnostic criteria for metabolic syndrome: caucasians versus African-Americans.

Stacey A Zeno1, Patricia A Deuster, Jennifer L Davis, Su-Jong Kim-Dorner, Alan T Remaley, Merrily Poth.   

Abstract

BACKGROUND: Metabolic syndrome is a constellation of risk factors used to identify individuals at greatest risk for developing cardiovascular disease (CVD). Early diagnosis of CVD would benefit African-Americans (AA), who have a higher prevalence of and mortality rate from CVD compared to Caucasians (CA). Two definitions for metabolic syndrome were used to classify healthy CA and AA, and evaluate how other CVD risk factors [C-reactive protein (CRP), percent body fat, fitness level, insulin resistance, and non-high-density lipoprotein cholesterol (HDL-C)] changed metabolic syndrome classification.
METHODS: Healthy AA (n = 97) and CA (n = 51) ranging from normal weight to obese, 18-45 years of age, with neither hypertension nor diabetes, were evaluated for cardiorespiratory fitness, height, weight, percent body fat, hip and waist circumference, blood pressure (BP), and fasting blood glucose, insulin, triglycerides, HDL, non-HDL-C, and CRP. Participants were classified as meeting the criteria for metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III 2004 (NCEP ATP III) and the International Diabetes Federation (IDF) definitions.
RESULTS: Significant ethnic differences (P < 0.01) in classification were noted for both metabolic syndrome definitions (NCEP ATP III, CA = 16.7% vs. AA = 5.7%; IDF, CA = 23.5% vs. AA = 8.2%). Ethnic differences were eliminated when fitness level or percent body fat was included as a criterion.
CONCLUSIONS: If diagnosis of metabolic syndrome is intended for early recognition of CVD risk and slowing CVD development, current definitions for metabolic syndrome will not capture healthy AA. Health-care providers may consider assessing percent body fat and participation in regular exercise, because these criteria would help identify AA at risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156068     DOI: 10.1089/met.2009.0053

Source DB:  PubMed          Journal:  Metab Syndr Relat Disord        ISSN: 1540-4196            Impact factor:   1.894


  6 in total

1.  Diabetic indicators are the strongest predictors for cardiovascular disease risk in African American adults.

Authors:  Ashley N Carter; Penny A Ralston; Iris Young-Clark; Jasminka Z Ilich
Journal:  Am J Cardiovasc Dis       Date:  2016-09-15

Review 2.  Low cardiorespiratory fitness in African Americans: a health disparity risk factor?

Authors:  Damon L Swift; Amanda E Staiano; Neil M Johannsen; Carl J Lavie; Conrad P Earnest; Peter T Katzmarzyk; Steven N Blair; Robert L Newton; Timothy S Church
Journal:  Sports Med       Date:  2013-12       Impact factor: 11.136

3.  The impact of race on metabolic disease risk factors in women with and without posttraumatic stress disorder.

Authors:  Eric A Dedert; Leia A Harper; Patrick S Calhoun; Michelle F Dennis; Jean C Beckham
Journal:  J Clin Psychol Med Settings       Date:  2013-03

4.  Genome-wide detection of allele specific copy number variation associated with insulin resistance in African Americans from the HyperGEN study.

Authors:  Marguerite R Irvin; Nathan E Wineinger; Treva K Rice; Nicholas M Pajewski; Edmond K Kabagambe; Charles C Gu; Jim Pankow; Kari E North; Jemma B Wilk; Barry I Freedman; Nora Franceschini; Uli Broeckel; Hemant K Tiwari; Donna K Arnett
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

Review 5.  Obesity and african americans: physiologic and behavioral pathways.

Authors:  Preetha Anna Abraham; Josh Ben Kazman; Stacey Anne Zeno; Patricia Anne Deuster
Journal:  ISRN Obes       Date:  2013-01-27

6.  The association between high-sensitivity C-reactive protein and metabolic risk factors in black and white South African women: a cross-sectional study.

Authors:  Cindy George; Juliet Evans; Lisa K Micklesfield; Tommy Olsson; Julia H Goedecke
Journal:  BMC Obes       Date:  2018-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.